Literature DB >> 22236582

Assessment of the Scopa-Aut questionnaire in multiple system atrophy: relation to UMSARS scores and progression over time.

Nathalie Damon-Perrière1, Alexandra Foubert-Samier, Valérie Cochen De Cock, Angélique Gerdelat-Mas, Rachel Debs, Anne Pavy-Le Traon, Jean-Michel Senard, Olivier Rascol, François Tison, Wassilios G Meissner.   

Abstract

Autonomic failure is a key feature of multiple system atrophy (MSA). Moreover, early autonomic failure is an independent predictive factor for rapid disease progression and shorter survival. The assessment of autonomic failure is therefore important for both, the diagnosis and prognosis of MSA. Here, we evaluate autonomic dysfunction in MSA patients by the Scopa-Aut questionnaire. Potential associations between the Scopa-Aut questionnaire and established markers of disease progression - that is the Unified MSA Rating Scale (UMSARS) - were further assessed. The results confirm early and prominent autonomic failure in MSA patients. Relative scores were highest for the sexual and urinary subdomains. Surprisingly, relative scores in the cardiovascular subdomain were lowest suggesting that the Scopa-Aut questionnaire is suboptimal for the screening and evaluation of cardiovascular symptoms in MSA. A multivariate regression showed an association between total Scopa-Aut and UMSARS I scores. No significant changes in Scopa-Aut scores were observed during follow-up except for the urinary subdomain, while UMSARS I, II and IV scores significantly increased over time. In conclusion, Scopa-Aut can be used as a simple auto-questionnaire for the screening of autonomic symptoms in multiple system atrophy. It seems not useful as endpoint for disease-modification or neuroprotection trials.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236582     DOI: 10.1016/j.parkreldis.2011.12.009

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  A cross-sectional study on drug use in multiple system atrophy.

Authors:  María Verónica Rey; Santiago Perez-Lloret; Anne Pavy-Le Traon; Wassilios G Meissner; Francois Tison; Olivier Rascol
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

2.  Cerebellar and parkinsonian phenotypes in multiple system atrophy: similarities, differences and survival.

Authors:  Dusan Roncevic; Jose-Alberto Palma; Jose Martinez; Niamh Goulding; Lucy Norcliffe-Kaufmann; Horacio Kaufmann
Journal:  J Neural Transm (Vienna)       Date:  2013-12-15       Impact factor: 3.575

3.  Dysautonomia is frequent in Machado-Joseph disease: clinical and neurophysiological evaluation.

Authors:  Karen A G Takazaki; Anelyssa D'Abreu; Anamarli Nucci; Iscia Lopes-Cendes; Marcondes C França
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

4.  Comparison of Different Symptom Assessment Scales for Multiple System Atrophy.

Authors:  Masaaki Matsushima; Ichiro Yabe; Koji Oba; Ken Sakushima; Yasunori Mito; Asako Takei; Hideki Houzen; Kazufumi Tsuzaka; Kazuto Yoshida; Yasunori Maruo; Hidenao Sasaki
Journal:  Cerebellum       Date:  2016-04       Impact factor: 3.847

Review 5.  Current Concepts in the Treatment of Multiple System Atrophy.

Authors:  Santiago Perez-Lloret; Olivier Flabeau; Pierre-Olivier Fernagut; Anne Pavy-Le Traon; María Verónica Rey; Alexandra Foubert-Samier; Francois Tison; Olivier Rascol; Wassilios G Meissner
Journal:  Mov Disord Clin Pract       Date:  2015-02-02

6.  Is There a Difference in Autonomic Dysfunction Between Multiple System Atrophy Subtypes?

Authors:  Divyani Garg; Achal Kumar Srivastava; Ashok Kumar Jaryal; Roopa Rajan; Akanksha Singh; Awadh Kishor Pandit; Deepti Vibha; Garima Shukla; Ajay Garg; Ravindra Mohan Pandey; Kameshwar Prasad
Journal:  Mov Disord Clin Pract       Date:  2020-04-09

Review 7.  Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies.

Authors:  Florian Krismer; Kurt A Jellinger; Sonja W Scholz; Klaus Seppi; Nadia Stefanova; Angelo Antonini; Werner Poewe; Gregor K Wenning
Journal:  Parkinsonism Relat Disord       Date:  2014-05-21       Impact factor: 4.891

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.